We describe a case series of 17 patients hospitalized in Manaus (western Brazilian Amazon) with PCR-confi rmed Plasmodium vivax infection who were treated with chloroquine and primaquine. The major complications were jaundice and severe anemia. No in vivo chloroquine resistance was detected. These data help characterize the clinical profi le of severe P. vivax malaria in Latin America.
D
uring [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] , in Latin America, a total of 7,554,993 cases of malaria were recorded; 5,507,167 (72.9%) of these cases were caused by Plasmodium vivax parasites. Of the P. vivax malaria cases, 3,833,477 were reported in Brazil, mainly in the Amazon Region (1) . Offi cial data from the Brazilian Ministry of Health identify Manaus as one of the leading cities in terms of number of P. vivax malaria cases in Latin America (2) .
Manaus (population 1,738,641 in 2009), the capital of the state of Amazonas in the western Brazilian Amazon, is clearly part of a new frontier in the economic development of the Amazon. In 2009, a total of 19,698 cases of malaria were reported in Manaus (annual parasitary index 11.3/1,000 population; 92.6% caused by P. vivax). Since the mid-1990s, as P. vivax was becoming the predominant malaria species in Brazil (3), severe cases and even deaths attributable to P. vivax infection have been reported anecdotally (3) . A concomitant trend of increased hospitalization of P. vivax-infected patients was seen in a Manaus tertiary care center (4) .
In 2000, one of the authors noted the increased clinical severity of P. vivax cases seen in this same hospital; the frequency of hospitalization was very similar to that of patients infected with P. falciparum (M.G.C.A., unpub. data). Other reports from the same reference center in Manaus have been published regarding unusual complications of P. vivax infection, such as severe rhabdomyolysis (5) and immune thrombocytopenic purpura (6) . At the same time, a cascade of reports from areas where P. vivax malaria is highly endemic confi rmed the clinical severity of the infections (7) . However, to date, data are lacking on the distribution of severe P. vivax malaria, the relationship of patient age, and the identifi cation of possible risk factors. This study describes the clinical features of P. vivax malaria in a case series of patients who were hospitalized in a tertiary care unit in the Brazilian Amazon and their clinical response to treatment with chloroquine.
The Study
The Tropical Medicine Foundation of Amazonas is a tertiary care center for infectious diseases in Manaus (3°8′S, 60°1′W). In 2001 and 2002, a total of 13,056 cases of malaria were diagnosed in this institution (11,251 P. vivax) , representing 65.1% of the total cases from Manaus. During the same period, 358 (3.2%) patients with P. vivax malaria were hospitalized. A retrospective analysis was performed of case-patients who fulfi lled the malaria severity criteria of the World Health Organization (WHO) (8) . These patients had an exclusive diagnosis of P. vivax malaria by thick blood smear (reviewed 2 times by experienced microscopists) and PCR, according to the technique described elsewhere (9) . PCR was performed on whole blood from all patients with P. vivax malaria, confi rmed by microscopy and any P. falciparum severity criterion recommended by WHO. Blood specimens were routinely stored by the laboratory of the institution at -70°C. Full clinical information was available from the patients' charts, and serologic tests for dengue virus, Leptospira spp., and hepatitis A, B, and C viruses were performed on available serum samples stored at -20°C.
Each patient was monitored for 28 days in outpatient clinics after beginning antimalarial treatment. Patients were routinely discharged only after parasitologic clearance and clinical recovery. Until 2006, chloroquine was still prescribed for patients with severe cases at a dose of 10 mg/kg on the fi rst day and 7.5 mg/kg on the second and third days, followed by primaquine (0.5 mg/kg/day for 7 days), according to the Brazilian Ministry of Health guidelines. In 2006, WHO formally recommended the treatment of severe vivax malaria to be the same as that for severe falciparum malaria, because of the risk for an unrecognized mixed infection (8) .
Seventeen patients were included in the analysis, and their clinical and laboratory data are shown in Tables 1 and  2 through a nasogastric tube) and primaquine. Acute respiratory distress syndrome (ARDS) (diffuse interstitial and alveolar infi ltrate by chest radiograph and partial O 2 pressure 40 mm Hg by arterial gas analysis) developed in patient 11 two days after she received chloroquine, and she died 3 days later. This patient had a negative thick blood smear from day 3 of treatment with choloroquine. The other 16 patients were followed up after discharge until day 28. None had clinical symptoms of malaria, and all thick blood smears were negative at days 7, 14, and 28. The patients in whom complications developed exhibited a remarkably wide age range (28 days-80 years). This age range is similar to that seen in other case series from Latin America, such as in hospitalized children from Venezuela with severe anemia that required blood transfusions (10) and in adults from Rondônia (a state in the western Brazilian Amazon) who had severe anemia, jaundice, acute renal failure, ARDS, and shock (11) . P. vivax malaria with ARDS has been reported in travelers who acquired the infection in Manaus (12, 13) . The fi nding of severe anemia in 4 of 7 children highlights the relevance of this complication in P. vivax infection (Figure) , as shown in a prospective study from Papua, Indonesia (14) . Nine patients sought treatment for cholestatic jaundice; for 8, jaundice was the only complication. The mechanisms involved are unknown.
The concomitant diagnosis of hepatitis A virus infection in patient 3 (Table 1) indicates that other infectious diseases should be excluded when characterizing severe P. vivax malaria. Also of note is the presence of thrombocytopenia in 15/17 patients (none had clinical bleeding), which suggests that this hematologic complication may be a surrogate marker of severity.
Conclusions
The wide range of parasitemia found in our patients does not enable us to comment on the value of this variable as a determinant of severity. Sixteen patients recovered without the use of antimicrobial drugs; therefore, it is highly improbable that bacterial sepsis was a factor for severity in our case series. In unstable transmission areas (<0.1 autochthonous case per 1,000 persons per year), malaria in older patients may pose an additional problem because chronic diseases (e.g., arterial hypertension and diabetes) may predispose a patient to clinical decompensation.
In vivo chloroquine resistance was not detected in any of the cases that were followed up, despite recent confi rmation of the phenomenon in this same locality (15) . Because a reliable molecular marker of chloroquine resistance is lacking and parenteral artemisinin derivatives are recommended for treatment of patients with severe P. vivax malaria, studies that assess clinical severity and chloroquine resistance would be unethical. However, our fi ndings suggest that chloroquine resistance would be a problem for individual patients and that the determinants of this resistance need to be clarifi ed. Clearly, areas with chloroquineresistant P. vivax also report severe P. vivax malaria, but we believe that these studies are not able to establish any fi rm causality. The fi nding of both phenomena in some areas may simply refl ect high transmission of this species.
Our retrospective review illustrates the spectrum of severe P. vivax malaria in Manaus, and these results parallel the increasing clinical severity described in malariaendemic areas such as Papua (Indonesia) and India. These severe P. vivax cases contribute to increased public health costs because of increased hospitalization and the need for intensive care and blood transfusions. The major complications in patients who required hospitalization were jaundice and severe anemia, although whether these complications were responsible for deaths is undetermined.
No clear severity criteria exist for P. vivax malaria. However, WHO criteria formerly defi ned for P. falciparum malaria seem to be applicable to most of the severe P. vivax malaria cases reported in hospital-based studies in the literature. PCR should be performed to rule out mixed infections and other common infectious diseases so that reports from different parts of the world are comparable. Despite the small number of patients, our data corroborate previous fi ndings of severe disease found in areas where chloroquine-resistant P. vivax is being reported but suggest that establishing direct causality is not straightforward. We urgently need to know which clinical complications in P. vivax malaria are associated with death to validate severity criteria. A valid biomarker for chloroquine resistance would also enable associative studies to determine the association between resistance and severity. 
